Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), rilpivirine/F/TAF (R/F/TAF) or F/TAF + another 3rd agent in HIV-1+patients over 24 months - Results from the German TAFNES cohort study-MedSci.cn

Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), rilpivirine/F/TAF (R/F/TAF) or F/TAF + another 3rd agent in HIV-1+patients over 24 months - Results from the German TAFNES cohort study

Stellbrink, H; Scholten, S; Hillenbrand, H; Knechten, H; Jessen, H; Schreiber, S; Goerner, K; Haubrich, R; Heinzkill, M

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020; 23 (): 54

科室
- - 订阅+
  - 更多科室
工具
服务